Medical weight loss is a physician-directed approach to weight management that considers the biological, metabolic, hormonal, lifestyle, and medical factors that influence body weight. Depending on the individual, treatment may include prescription weight-loss medication, nutrition and exercise strategies, metabolic evaluation, body-composition monitoring, and treatment of contributing health conditions.
At Performance Men's Health, the objective is not simply to lower the number on the scale. We focus on losing excess fat, preserving muscle, improving metabolic health, and developing a strategy for maintaining results over time.
Traditional dieting generally relies on reducing calorie intake through changes in food choices and portion size. While nutrition remains essential, body weight is also regulated by complex interactions between the brain, gastrointestinal tract, hormones, metabolism, adipose tissue, genetics, environment, and behavior.
Medical weight management allows us to evaluate these factors and, when appropriate, use medications that influence biological pathways involved in hunger, satiety, food reward, and glucose regulation. This can make achieving and sustaining an appropriate calorie intake considerably more manageable for some patients.
Medical weight management may be appropriate for men with obesity or overweight accompanied by weight-related health concerns, particularly when lifestyle interventions alone have not produced adequate or sustainable results.
Evaluation may include weight and weight trajectory, waist circumference, visceral fat and body composition, blood pressure, cholesterol, insulin resistance or prediabetes, metabolic liver disease, sleep apnea, cardiovascular risk, previous weight-loss attempts, medications, nutrition, exercise, sleep, and hormonal factors when clinically relevant.
Not every man who wants to become leaner needs medication. The decision should be based on the individual's health, body composition, metabolic risk, and treatment goals.
No. FDA-approved weight-loss medications may be prescribed to adults with obesity, as well as adults who are overweight and have at least one weight-related health condition, such as high blood pressure, abnormal cholesterol, prediabetes or type 2 diabetes, cardiovascular disease, or sleep apnea.
In some circumstances, GLP-1–based medications may also be prescribed off-label after an individualized discussion of the potential benefits, risks, and treatment goals with your provider.
Medical weight management considers more than BMI alone. Abdominal and visceral fat, body composition, metabolic health, and overall health risk can all be relevant when determining an appropriate treatment strategy.
Weight regulation is complex, and there is rarely a single explanation. Genetics, age, appetite regulation, insulin resistance, declining physical activity, loss of muscle mass, sleep, stress, medications, alcohol intake, nutrition, and certain hormonal or medical conditions can all contribute.
For many men, increasing visceral fat - the metabolically active fat stored deeper within the abdomen - is particularly important because it is closely associated with insulin resistance, cardiovascular risk, metabolic liver disease, sleep apnea, and lower testosterone in some men.
GLP-1–based medications influence hormonal and neurological pathways involved in appetite, satiety, food intake, digestion, and glucose regulation. Semaglutide, the active medication in Wegovy®, acts through the GLP-1 receptor. Tirzepatide, the active medication in Zepbound®, acts through both GIP and GLP-1 receptors.
For many patients, these medications reduce hunger, increase fullness after eating, decrease cravings, and reduce persistent thoughts about food sometimes described as "food noise." They can also influence food-reward signaling and improve glucose regulation.
They do not replace nutrition and exercise, but they can change some of the biological signals that make sustained weight loss difficult.
Wegovy contains semaglutide, a GLP-1 receptor agonist. Zepbound contains tirzepatide, which acts through both GIP and GLP-1 receptors. Both are FDA-approved for chronic weight management in appropriate adults, but they differ in mechanism, formulation, clinical evidence, and additional FDA-approved indications.
Zepbound has produced greater average weight loss in direct comparative research and is also FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity. Wegovy has an FDA indication for reducing cardiovascular death, heart attack, and stroke in certain adults with established cardiovascular disease and overweight or obesity.
Wegovy is available in oral and injectable formulations, while Zepbound is currently administered by injection.
Neither medication is universally better. Treatment selection should reflect medical history, metabolic and cardiovascular health, weight-loss goals, tolerability, route of administration, cost or coverage, and individual preference.
On average, Zepbound has produced greater weight loss in direct comparative research. In the SURMOUNT-5 trial, adults with obesity but without type 2 diabetes lost an average of 20.2% of body weight with tirzepatide compared with 13.7% with semaglutide over 72 weeks.
Greater average weight loss does not automatically make Zepbound the better medication for every patient. The appropriate choice depends on medical history, cardiovascular and metabolic health, weight-loss goals, side effects, treatment response, route of administration, and individual preference.
Results vary substantially by medication and individual.
In the landmark STEP 1 trial, adults without diabetes taking once-weekly injectable semaglutide lost approximately 15% of their starting body weight on average over 68 weeks. Tirzepatide has produced average weight reductions approaching or exceeding 20% at higher doses in major trials involving adults without diabetes.
These averages should not be interpreted as predictions. Starting weight, medication, dose, treatment duration, metabolic health, nutrition, physical activity, tolerability, and individual biology all influence results.
The goal should be the right amount and quality of weight loss - not necessarily the maximum amount possible.
Yes. Effective oral GLP-1 medications are now available for patients who prefer to avoid injections.
Oral Wegovy (semaglutide) produced approximately 13.6% average weight loss in its pivotal trial, while Foundayo (orforglipron), a once-daily oral GLP-1 medication, produced approximately 11% average weight loss at its highest approved dose.
The choice between oral and injectable treatment often comes down to patient preference. Patients and providers should also consider practical differences in dosing, including timing around food and beverages with certain oral formulations.
Medical weight loss generally occurs gradually over many months. Some patients notice changes in hunger, fullness, or cravings relatively early, but medications such as Wegovy and Zepbound are intentionally titrated over time.
The appropriate rate of weight loss varies. Losing weight too aggressively can make adequate nutrition and muscle preservation more difficult, so treatment should balance progress with metabolic health, strength, body composition, and tolerability.
The most common side effects of medications such as Wegovy and Zepbound involve the gastrointestinal system and may include nausea, diarrhea, vomiting, constipation, abdominal discomfort, indigestion, and reflux. These effects are often most noticeable when treatment begins or the dose increases.
Less common but more serious concerns can include pancreatitis, gallbladder disease, severe gastrointestinal symptoms, and dehydration-related kidney injury. GLP-1–based medications also carry important warnings and contraindications related to medullary thyroid carcinoma and MEN2.
Individual medical history should be reviewed before treatment. Gradual titration, appropriate dosing, and medical monitoring can help improve tolerability and identify potential problems early.
Some loss of lean mass is common with any significant weight loss, including weight loss with GLP-1–based medications. Current evidence does not establish that these medications directly cause skeletal muscle wasting.
Muscle loss is influenced by factors including the amount and rate of weight loss, inadequate calorie or protein intake, age, baseline muscle mass, and physical activity.
At Performance Men's Health, we generally emphasize adequate protein intake - often approximately 1.2–1.6 g/kg per day depending on the individual - along with progressive resistance training approximately three days per week. We also monitor body composition rather than simply body weight.
The goal is to lose excess fat while preserving as much muscle as possible.
Yes. Excess weight - particularly visceral abdominal fat - is closely associated with insulin resistance and progression toward prediabetes and type 2 diabetes.
Meaningful weight loss can improve insulin sensitivity, blood glucose, and HbA1c and may also improve blood pressure, triglycerides, metabolic liver disease, and other cardiometabolic risk factors.
Clinical trials of semaglutide and tirzepatide have also demonstrated substantial improvements in glucose regulation and reduced progression from prediabetes to type 2 diabetes in certain populations.
For men with metabolic dysfunction, these improvements may be more clinically important than the change on the scale itself.
Yes, in some men. Excess body fat - particularly visceral fat - and metabolic dysfunction are associated with lower testosterone levels in some patients. When obesity, insulin resistance, or metabolic dysfunction are contributing to lower testosterone, meaningful weight loss may improve natural testosterone production.
Lifestyle changes that reduce visceral fat, increase physical activity, improve sleep, and support metabolic health may further contribute. For men with borderline or mildly low testosterone, it can be helpful to monitor levels as body composition and metabolic health improve.
Weight-loss medication itself is not testosterone therapy, however. Men with persistent symptoms suggestive of testosterone deficiency should be evaluated independently.
Yes. Depending on the specific medication and patient population, some GLP-1–based therapies have demonstrated important health benefits beyond weight loss.
Wegovy (semaglutide) is FDA-approved to reduce cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and overweight or obesity. Zepbound (tirzepatide) is FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
Clinical research has also demonstrated benefits involving heart failure, kidney disease, metabolic liver disease, visceral fat, and other measures of cardiometabolic health in specific patient populations.
Other potential applications remain under investigation. GLP-1–based therapies are being studied for their effects on alcohol and other addictive behaviors, brain reward pathways, and neurodegenerative diseases. These areas are promising but should not yet be considered established clinical benefits.
There is no universal treatment duration. Wegovy and Zepbound are intended for chronic weight management, and continued treatment should be individualized based on clinical benefit, weight trajectory, metabolic health, tolerability, patient preference, and the ability to maintain results.
Long-term treatment does not necessarily mean every patient must remain indefinitely on the same medication or dose. Maintenance strategies may evolve as weight, body composition, health, and treatment goals change.
Weight regain is common after GLP-1 or GIP/GLP-1 therapy is discontinued. These medications influence biological pathways involved in appetite and weight regulation; when treatment stops, hunger and food intake may increase again.
This is why we believe the maintenance strategy should begin before the weight-loss phase ends. Depending on the individual, long-term management may involve continued medication, individualized maintenance dosing, a change in therapy, or carefully monitored discontinuation alongside nutrition, exercise, sleep, and muscle-preservation strategies.
Yes, although we prefer to think in terms of nutrition and body composition rather than simply "dieting."
Weight-loss medications can reduce hunger and make appropriate portions easier to maintain, but they do not replace high-quality nutrition, adequate protein, resistance training, cardiovascular exercise, sleep, or other behaviors that support long-term health.
Resistance training and adequate protein are particularly important for men because they help preserve muscle during weight loss. The objective is to use medication, when appropriate, to make a healthier body composition and metabolic state more achievable - and then build the habits and treatment strategy needed to maintain it.
No. Medication can be a powerful tool, but it is only one part of medical weight management.
At Performance Men's Health, we evaluate factors that may contribute to weight gain or make weight loss more difficult, including metabolic health, insulin resistance, sleep, medications, testosterone, and other hormonal factors when appropriate. Comprehensive laboratory testing and body composition analysis help guide treatment and establish a baseline.
For patients using weight-loss medication, we monitor progress beyond the number on the scale - including changes in visceral fat and muscle mass - and emphasize adequate protein, resistance training, sleep, and other strategies that support muscle preservation and metabolic health.
The goal is not simply to lose weight, but to improve body composition and metabolic health while building a strategy that can be maintained long term.
Schedule a consultation with the Performance Men's Health team.